Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 308Nivolumab 160Carboplatin 158Cisplatin 140Cyclophosphamide 137Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 92Dexamethasone 88Gemcitabine 88Ipilimumab 83Biopsy 81Docetaxel 78Doxorubicin 76Rituximab 70Etoposide 69Lenalidomide 61durvalumab 61Radiation 60Prednisone 59atezolizumab 59Taxes 58Pemetrexed 57fludarabine 55Bevacizumab 54Cytarabine 52Vincristine 52olaparib 52Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bupropion × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡